Actively Recruiting
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
Led by Shanghai Eye Disease Prevention and Treatment Center · Updated on 2026-05-07
158
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if repeated low-level red light (RLRL) therapy works to treat pathologic myopia in adults. It will also learn about the safety of RLRL. The main questions it aims to answer are: Does RLRL modulate choroidal microcirculation to retard retinal atrophy in pathological myopia? What medical problems do participants have when receiving RLRL therapy? Researchers will compare RLRL to a sham RLRL device (identical in appearance but delivering \<10% of the original device's energy output) to see if RLRL works to treat pathologic myopia. Participants will: Take RLRL or sham RLRL twice daily, 3 minutes per session, 5 days per week, for a total duration of 12 months. Visit the clinic once every 3 months for checkups and tests Keep a diary of their symptoms and their visual perception
CONDITIONS
Official Title
LED Red Light in Modulating Choroidal Microcirculation to Retard Retinal Atrophy in Pathological Myopia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 55 years
- Best corrected visual acuity (BCVA) of 0.1 or better (LogMAR 1.0 or less)
- Diagnosed with high myopia: spherical equivalent (SE) of -6.00 diopters or less and axial length (AL) of 26.0 mm or more
- Pathological fundus changes meeting one of the following: Category 2 (diffuse chorioretinal atrophy), Category 3 (patchy chorioretinal atrophy), or Category 4 (macular atrophy with choroidal neovascularization) of META-PM classification; or Category 1 complicated with macular schisis; or BCVA less than 0.6
You will not qualify if you...
- Other eye diseases affecting vision or assessment, including active myopic choroidal neovascularization needing anti-VEGF, macular hole, vitreous hemorrhage, diabetic retinopathy, retinal detachment, retinal vein occlusion, optic neuritis, uveitis, severe cataract, and glaucoma
- Systemic conditions like photosensitive epilepsy, autoimmune diseases (e.g., systemic lupus erythematosus), or pregnancy/lactation
- Eye surgery, laser treatment, or eye medication within 3 months before enrollment
- Inability to attend regular follow-ups or cognitive impairment
- Opaque eye media that prevent fundus examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Eye Disease Prevention and Treatment Center
Shanghai, China
Actively Recruiting
Research Team
Y
Yan Xu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here